quillichew er Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quillichew Er, and when can generic versions of Quillichew Er launch?
Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-eight patent family members in fourteen countries.
The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quillichew Er
A generic version of quillichew er was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for quillichew er?
- What are the global sales for quillichew er?
- What is Average Wholesale Price for quillichew er?
Summary for quillichew er
International Patents: | 38 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Clinical Trials: | 1 |
Patent Applications: | 3,514 |
Drug Prices: | Drug price information for quillichew er |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for quillichew er |
What excipients (inactive ingredients) are in quillichew er? | quillichew er excipients list |
DailyMed Link: | quillichew er at DailyMed |
Recent Clinical Trials for quillichew er
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer | Phase 4 |
Pharmacology for quillichew er
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
Paragraph IV (Patent) Challenges for QUILLICHEW ER
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
QUILLICHEW ER | Extended-release Chewable Tablets | methylphenidate hydrochloride | 20 mg, 30 mg and 40 mg | 207960 | 1 | 2016-04-25 |
US Patents and Regulatory Information for quillichew er
quillichew er is protected by ten US patents.
Patents protecting quillichew er
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Modified release formulations containing drug-ion exchange resin complexes
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Orally effective methylphenidate extended release powder and aqueous suspension product
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
Methylphenidate extended release chewable tablet
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-002 | Dec 4, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for quillichew er
See the table below for patents covering quillichew er around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2008140944 | КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА | ⤷ Sign Up |
Denmark | 2018160 | ⤷ Sign Up | |
Israel | 227734 | אבקה בעלת שחרור מושהה ותרחיף מימי המכיל מתילפנידאט (Extended release powder and aqueous suspension comprising methylphenidate) | ⤷ Sign Up |
Australia | 2017202955 | Extended release powder and aqueous suspension comprising methylphenidate | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |